Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nilutamide: possible utility as a second-line hormonal agent.

A Desai1, W M Stadler, N J Vogelzang

  • 1Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.

Urology
|December 18, 2001
PubMed
Summary

Nilutamide may induce prostate-specific antigen (PSA) responses in some patients with hormone-resistant prostate cancer previously treated with antiandrogens. This suggests nilutamide could be a valuable option for patients with advanced prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.

ESMO open·2026
Same author

Patient Reported Satisfaction Outcomes After Breast Radiation Using Intraoperative Radiation Therapy vs. External Beam Radiation Therapy.

European journal of breast health·2026
Same author

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Search for Extremely-High-Energy Neutrinos and First Constraints on the Ultrahigh-Energy Cosmic-Ray Proton Fraction with IceCube.

Physical review letters·2025
Same author

Measurement of Atmospheric Neutrino Oscillation Parameters Using Convolutional Neural Networks with 9.3 Years of Data in IceCube DeepCore.

Physical review letters·2025
Same author

Search for an eV-Scale Sterile Neutrino Using Improved High-Energy ν_{μ} Event Reconstruction in IceCube.

Physical review letters·2024

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Hormone-resistant prostate cancer (HRPC) poses treatment challenges, often involving resistance to standard antiandrogen therapies.
  • Resistance mechanisms may include androgen receptor (AR) mutations or overexpression, necessitating alternative treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy of nilutamide in inducing prostate-specific antigen (PSA) responses in HRPC patients pre-exposed to antiandrogens.
  • To explore nilutamide's potential to overcome resistance mediated by altered AR binding.

Main Methods:

  • Retrospective analysis of 14 HRPC patients treated with nilutamide (150 mg/day or 300 mg/day).
  • Patients had prior exposure to bicalutamide, flutamide, or both, with some also receiving chemotherapy.

Main Results:

Related Experiment Videos

  • 50% (7/14) of patients achieved a PSA decline >50%.
  • Median PSA response duration was 11 months; 2 patients maintained response.
  • 20% (3/14) showed minor PSA responses; 4/6 patients with bone pain reported subjective improvement.

Conclusions:

  • Nilutamide can induce PSA responses in a subset of HRPC patients progressing on prior antiandrogen therapy.
  • Nilutamide shows potential as an alternative antiandrogen in managing advanced prostate cancer.
  • Further prospective studies are warranted to define nilutamide's role in HRPC treatment.